Results 41 to 50 of about 40,707 (134)

Herpes Encephalitis: A Mortal Complication in a Patient Treated with Immunosuppressive Drugs because of Immune-Related Adverse Events after Ipilimumab Treatment

Case Reports in Oncology, 2017
Until a few years ago, metastatic melanoma had a poor prognosis with limited treatment options. These therapeutics options and thereby median survival have increased obviously over 5 years with the arrival of immunotherapeutic drugs like ipilimumab ...
Lieke van Montfort, Caroline M. Loos, Monique Anten, Rob L.H. Jansen   +3 more
doaj   +1 more source

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

Journal for ImmunoTherapy of Cancer, 2019
Purpose To investigate the efficacy and safety of concurrent stereotactic radiosurgery (SRS) and ipilimumab or nivolumab in patients with untreated melanoma brain metastases.
Giuseppe Minniti, Dimitri Anzellini, Chiara Reverberi, Gian Carlo Antonini Cappellini, Luca Marchetti, Federico Bianciardi, Alessandro Bozzao, Mattia Osti, Pier Carlo Gentile, Vincenzo Esposito   +9 more
doaj   +1 more source

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Journal for ImmunoTherapy of Cancer, 2018
Background Nivolumab plus ipilimumab improves overall survival and is associated with less toxicity compared with sunitinib in the first-line setting of advanced renal-cell carcinoma (RCC).
Bin Wu, Qiang Zhang, Jie Sun
doaj   +1 more source

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Case Reports in Oncology, 2018
Immune checkpoint inhibitors such as ipilimumab, a cytotoxic T-lymphocyte-associated antigen-4 inhibitor, have been widely used for advanced malignancies.
Yoshito Nishimura, Miho Yasuda, Kazuki Ocho, Masaya Iwamuro, Osamu Yamasaki, Takehiro Tanaka, Fumio Otsuka   +6 more
doaj   +1 more source

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations

EJC Skin Cancer
Immunotherapy has dramatically changed the outcome for patients with advanced melanoma, with significant improvements in overall survival and potential cure for some.
Sophia Kreft, Tommaso Bosetti, Rebecca Lee, Paul Lorigan   +3 more
doaj   +1 more source

Late-Onset Inflammatory Bowel Disease-Like Syndrome after Ipilimumab Therapy: A Case Report

Case Reports in Oncology, 2017
Background: Antitumor immunotherapy has become a major player in cancer therapy. Ipilimumab is a humanized monoclonal antibody against the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an important downregulator of T-cell activation.
Reem Akel, Bilal Anouti, Arafat Tfayli
doaj   +1 more source

Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma

Case Reports in Dermatology, 2017
A 47-year-old female patient with rheumatoid arthritis (RA) treated with methotrexate, was diagnosed with metastatic melanoma. After surgical removal of the tumor, the patient started treatment with ipilimumab while methotrexate was stopped.
Nicoletta F. Jaberg-Bentele, Michael Kunz, Shatha Abuhammad, Reinhard Dummer   +3 more
doaj   +1 more source

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

Journal for ImmunoTherapy of Cancer, 2016
Background High dose interleukin-2 (HD IL-2) can induce durable responses in a subset of patients leading to long-term survival. Immune checkpoint blockade (ICB) has demonstrated similarly durable responses in a larger proportion of patients.
Sandra Aung, Sigrun Hallmeyer, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Gregory A. Daniels, Sapna P. Patel, John M. Kirkwood, Ryan J. Sullivan, Marc S. Ernstoff, Brendan D. Curti, Elizabeth I. Buchbinder, Rene Gonzalez, John M. Richart, Anasuya Gunturi, Jessica Perritt, Janice Dutcher, Girald P. Miletello, Joe Lutzky, Michael A. Morse   +19 more
doaj   +1 more source

Durability of Response with First-Line Combined Immune Checkpoint Inhibitor Therapy Compared to Checkpoint Inhibitor with VEGFR-TKI in Advanced Clear Cell Renal Cell Carcinoma

Kidney Cancer
Over the past several years, four regimens incorporating immune checkpoint inhibitors have become widely used in the front-line setting to treat metastatic clear cell renal cell carcinoma: nivolumab with ipilimumab, axitinib with pembrolizumab ...
Jacob Zaemes, David F. McDermott, Meredith M. Regan, Michael B. Atkins   +3 more
doaj   +1 more source

Profile of ipilimumab and its role in the treatment of metastatic melanoma

Drug Design, Development and Therapy, 2011
Sapna P Patel, Scott E WoodmanMelanoma Medical Oncology Department, University of Texas, MD Anderson Cancer Center, Houston, TX, USAAbstract: Melanoma is an immunogenic cancer.
Patel SP, Woodman SE
doaj